Holdings derived from the most recent reported transactions. Not adjusted for stock splits or share-class conversions.
| Issuer | Shares | Source | Last tx | Detail |
|---|---|---|---|---|
| CG Oncology, Inc. | 4,558,812 | reported | 29 Jan 2024 | tx 5+4,028,198−34,594,896 |
| BeyondSpring Inc. | 1,870,600 | reported | 16 Sept 2025 | tx 6−9,820 |
| Nivalis Therapeutics, Inc. | 1,735,544 | reported | 09 Nov 2023 | tx 1+375,000 |
| Date | Type | Issuer | Qty | Price | Signals |
|---|---|---|---|---|---|
| 12 Sept 2025 | SALE | BeyondSpring Inc. | 700 | 1.85 USD | |
| 16 Sept 2025 | SALE | BeyondSpring Inc. | 840 | 1.88 USD | |
| 15 Sept 2025 | SALE | BeyondSpring Inc. | 2,570 | 1.84 USD | |
| 25 Aug 2025 | SALE | BeyondSpring Inc. | 300 | 1.77 USD | |
| 22 Aug 2025 | SALE | BeyondSpring Inc. | 2,376 | 1.75 USD | |
| 21 Aug 2025 | SALE | BeyondSpring Inc. | 3,034 | 1.79 USD | |
| 29 Jan 2024 | CONVERSION | CG Oncology, Inc. | 3,628,198 | — | |
| 29 Jan 2024 | PURCHASE | CG Oncology, Inc. | 400,000 | 19.00 USD | |
| 29 Jan 2024 | CONVERSION | CG Oncology, Inc. | 8,644,891 | — | deriv |
| 29 Jan 2024 | CONVERSION | CG Oncology, Inc. | 4,402,320 | — | deriv |
| 29 Jan 2024 | CONVERSION | CG Oncology, Inc. | 21,547,685 | — | deriv |
| 09 Nov 2023 | PURCHASE | Nivalis Therapeutics, Inc. | 375,000 | 12.50 USD |